Navigation Links
Pharma IQ's Drug Recalls Industry Outline
Date:8/24/2012

LONDON, August 24, 2012 /PRNewswire/ --

Pharma IQ has just produced the Drug Recalls Industry Outline, where it analyses the challenges and implications of the late stage development failures. Pharma IQ had a quick look back over the last few years to see a timeline of drug failures and recalls at the late stages of development.

'Some of the key time saving strategies and information sources to make these decisions are trial design approaches, imaging techniques, biomarkers, strategic outsourcing and patient recruitment' says Nicola Ambler, Senior Conference Director, Pharma IQ, who is directing the upcoming Innovation in Phase 1 Clinical Development in Milan this September.

The outline analyses the drug withdrawals in the latter stages. In August 2012, Pfizer and J&J announced they were going to stop the development of the Alzheimer's drug, Bapineuzumab.  In March 2012 AstraZeneca and Targacept announced that their partnered depression drug - TC-5214 - failed at Phase III. The last two of four late-stage studies failed to meet their primary endpoints, eliminating plans for a comeback after the first two Phase III studies also ended in failure. In March 2011 Sanofi-Aventis' lung cancer drug aflibercept failed to meet its primary endpoint in a phase III trial.

The Drug Recalls Industry Outline can be accessed at http://www.phase1clinicaldevelopment.com/news

The Industry Outline was created as a part of the pre-conference preparation for the 3th Innovation in Phase I Clinical Development Forum taking place 17-19 September, 2012 in Milan. The agenda and final speaker line-up feature JW McBlane, Pharmaceutical Assessor, MHRA that will lead the session Early Clinical Studies - A Regulator's Expectations for Complex Protocols and Complex Productsand  Corina Dota, ECG Centre Director, Co-chair Cardiac QT/Arrhythmia Safety Knowledge Group from AstraZeneca presenting the case study Designing and Integrating a Robust Cardiac Safety Strategy.

Other important topics that will be discussed at the event include:

  • Biomarker development and early strategies for patients selection (case study from Roche);
  • Overcoming the internal and external challenges of developing the right biomarker at the right time (open discussion with Lundbeck);
  • Potential impact of ICH guidelines (M3, S9 and S6) on the scientific based non clinical assessment to achieve faster regulatory decisions on anticancer Phase One Clinical Trials (Italian Health Ministry)

To access the full Overview or to find out more about Phase I Clinical Development Forum 2012 please visit http://www.phase1clinicaldevelopment.com/news, email  enquire@iqpc.co.uk or call +44(0)2073689421.

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Joanna Checinska (joanna.checinska@iqpc.co.uk)

Media contact: Joanna, +44(0)20-7368-9421, joanna.checinska@iqpc.co.uk  - Please contact for more information or images.


'/>"/>
SOURCE Pharma IQ
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):